BIONDVAX PHARMACEUTICALS-ADR (BVXV) Stock Analyst Ratings
USA - NASDAQ:BVXV - US09073Q2049 - ADR
1.36 USD
+0.05 (+3.82%)
1.38 USD
+0.02 (+1.47%)
ChartMill assigns a Buy % Consensus number of 83% to BVXV. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 39.78. This target is 2825% above the current price.
BVXV was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about BVXV.
In the previous month the buy percentage consensus was at a similar level.
BVXV was analyzed by 7 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-01-26 | Aegis Capital | Initiate | Buy |
BIONDVAX PHARMACEUTICALS-ADR / BVXV FAQ
What do analysts expect the price target to be for BIONDVAX PHARMACEUTICALS-ADR (BVXV)?
7 analysts have analysed BVXV and the average price target is 39.78 USD. This implies a price increase of 2825% is expected in the next year compared to the current price of 1.36.
How do analysts rate BIONDVAX PHARMACEUTICALS-ADR (BVXV)?
The consensus rating for BIONDVAX PHARMACEUTICALS-ADR (BVXV) is 82.8571 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts cover BIONDVAX PHARMACEUTICALS-ADR (BVXV) stock?
The number of analysts covering BIONDVAX PHARMACEUTICALS-ADR (BVXV) is 7.